Rani Therapeutics Holdings, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: every model's value for Rani Therapeutics Holdings, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.
Rani Therapeutics Holdings, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Rani Therapeutics has little or no product revenue yet; it used $20m of cash in the twelve months to June 2026. It passes 2 of our 3 financial-health checks.
Our model value for Rani Therapeutics Holdings is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Rani Therapeutics Holdings, Inc.'s trailing-twelve-month revenue grew 306.4% year on year, with a free-cash-flow margin of -417.0%. Where it stands out: long-term debt as % of assets of 0.0% ranks 1 of 78 biotechnology companies we cover. Where it lags: days sales outstanding of 153 days ranks 87 of 100 biotechnology companies we cover.
Current signal Revenue growth accelerating: TTM revenue growth rose to 306.4% (+142.3pp vs the prior quarter).
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Rani Therapeutics Holdings, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.14 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | — | Does not apply: the projected cash flows don't support a positive value |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$0.1 ~$0.1–$0.4 | Left out: out of range vs price (0.20x) |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Rani Therapeutics Holdings, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Share price | $16.35 | $5.90 | $3.32 | $1.37 | $1.35 |
| Market value | $319381 | $140520 | $84677 | $39012 | $89286 |
| + Net debt (− = net cash) | −$117m | $3m | $24m | $21m | −$19m |
| Enterprise value | −$117m | $3m | $24m | $21m | −$19m |
| Multiples | |||||
| Price / sales | 0.1x | — | — | 0.0x | 0.1x |
| Price / earnings | — | — | — | — | — |
| Price / free cash flow | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Next results: November 5, 2026. Analysts expect revenue of $1m and EPS of −$0.05 (range −$0.05 to −$0.04) for the quarter.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.17 | +62% | $6m | +283% |
| Next | −$0.19 | −10% | $7m | +6% |
The consensus EPS forecast for the current fiscal year is −15.4% on 90 days ago. In the last 30 days, 2 analysts raised Rani Therapeutics Holdings, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.20 | −$0.23 |
| 60 days ago | −$0.19 | −$0.22 |
| 30 days ago | −$0.18 | −$0.21 |
| 7 days ago | −$0.18 | −$0.21 |
| Now | −$0.17 | −$0.19 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.05 | −$0.04 | +20.0% |
| Mar 2026 | −$0.04 | −$0.04 | +7.7% |
| Dec 2025 | −$0.07 | −$0.07 | −5.0% |
| Sept 2025 | −$0.12 | −$0.12 | +2.7% |
Adjusted EPS as companies report it, against the average analyst estimate.
Last 12 months −74.9%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $1m | $5m | +306.4% |
| P/S multiple | n/m | 19.8x | −91.4% |
| Share count | 125m | 175m | −28.4% |
Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.
| Calendar year | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|
| Return | |||||
| RANI | −64% | −44% | −59% | −2% | −59% |
| Industry peers (median) | −56% | −17% | −28% | −5% | −26% |
| S&P 500 | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | |||||
| RANI | 33% | 42% | 42% | 33% | 46% |
| S&P 500 | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | |||||
| RANI | −76% | −73% | −83% | −78% | −63% |
| S&P 500 | −25% | −10% | −8% | −19% | −9% |
Worst fall since July 30, 2021: 99% from November 18, 2021 to July 16, 2025. Getting back needed a 8437% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 13, 2026 | −0.9% | +0.5% | +6.0% | +4.1% |
| May 15, 2026 | −12.4% | −1.3% | −3.6% | −31.5% |
| March 26, 2026 | −28.9% | −3.5% | −26.3% | −21.9% |
| November 6, 2025 | −19.2% | −1.0% | −22.8% | −37.6% |
| August 7, 2025 | −4.0% | +0.7% | +1.3% | −9.1% |
| May 13, 2025 | −9.1% | +0.8% | +22.2% | −8.5% |
| March 31, 2025 | −9.6% | +1.0% | −17.6% | −18.4% |
| November 14, 2024 | −8.1% | −1.9% | −17.4% | −35.6% |
| May 6, 2024 | +4.3% | +1.1% | −14.5% | −29.5% |
| March 20, 2024 | +1.4% | +1.3% | −14.6% | +99.2% |
| November 8, 2023 | −3.0% | −0.7% | +0.5% | +58.6% |
| November 1, 2023 | −3.1% | +3.0% | +1.0% | +24.5% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY21 Q1 | $1.1M |
| FY21 Q2 | $3M |
| FY21 Q3 | $2.9M |
| FY21 Q4 | $2.7M |
| FY24 Q4 | $1M |
| FY25 Q1 | $1.2M |
| FY25 Q2 | $1.2M |
| FY25 Q3 | $1.2M |
| FY25 Q4 | $1.6M |
| FY26 Q1 | $3.2M |
| FY26 Q2 | $4.9M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY21 Q1 | -1442.6% |
| FY21 Q2 | -600.6% |
| FY21 Q3 | -1475.3% |
| FY21 Q4 | -1899.1% |
| FY24 Q4 | -5186.3% |
| FY25 Q1 | -4274.5% |
| FY25 Q2 | -4106.3% |
| FY25 Q3 | -3727.8% |
| FY25 Q4 | -2346.0% |
| FY26 Q1 | -1093.0% |
| FY26 Q2 | -675.8% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY21 Q2 | -533.7% |
| FY21 Q3 | -956.2% |
| FY21 Q4 | -1205.4% |
| FY24 Q4 | -3479.0% |
| FY25 Q1 | -2878.7% |
| FY25 Q2 | -2604.5% |
| FY25 Q3 | -2315.2% |
| FY25 Q4 | -1151.4% |
| FY26 Q1 | -540.0% |
| FY26 Q2 | -417.0% |
| Fiscal year | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|---|
| Income | |||||||
| Revenue | 0 | 3 | 0 | 0 | 1 | 2 | 5 |
| EBITDA | −16 | −51 | −63 | −65 | −52 | −37 | −32 |
| Operating income | −17 | −52 | −63 | −66 | −53 | −38 | −33 |
| Net income | −17 | −8 | −31 | −34 | −30 | −30 | −30 |
| Diluted EPS | — | −$0.43 | −$1.28 | −$1.33 | −$1.05 | −$0.45 | — |
| Growth (year on year) | |||||||
| Revenue | — | +488.1% | −100.0% | — | — | +58.9% | +306.4% |
| Margins | |||||||
| EBITDA margin | <−999% | <−999% | — | — | <−999% | <−999% | −660.0% |
| Operating margin | <−999% | <−999% | — | — | <−999% | <−999% | −675.8% |
| Net margin | <−999% | −306.6% | — | — | <−999% | <−999% | −618.0% |
| Free-cash-flow margin | <−999% | <−999% | — | — | <−999% | <−999% | −417.0% |
| Cash flow | |||||||
| Cash from operations | −15 | −32 | −47 | −51 | −35 | −19 | −20 |
| Capital spending | 1 | 1 | 2 | 1 | 0 | 0 | 0 |
| Free cash flow | −16 | −33 | −48 | −52 | −36 | −19 | −20 |
| Stock-based pay | 0 | 23 | 16 | 19 | 16 | 12 | 9 |
| Free cash flow after stock pay | −16 | −55 | −64 | −71 | −52 | −31 | −29 |
| Balance sheet | |||||||
| Cash | 73 | 117 | 27 | 6 | 4 | 19 | 5 |
| Total debt | 4 | 0 | 30 | 30 | 25 | 0 | 0 |
| Net debt (negative = net cash) | −69 | −117 | 3 | 24 | 21 | −19 | −5 |
| Diluted shares | — | — | — | — | — | — | — |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 2 |
| EBITDA | −12 | −15 | −12 | −10 | −7 | −8 | −8 | −9 |
| Operating income | −12 | −15 | −12 | −11 | −7 | −9 | −8 | −9 |
| Net income | −7 | −9 | −7 | −7 | −5 | −10 | −7 | −7 |
| Diluted EPS | −$0.24 | −$0.27 | −$0.22 | −$0.18 | −$0.12 | $0.05 | −$0.04 | −$0.04 |
| Growth (year on year) | ||||||||
| Revenue | — | — | — | — | — | +42.1% | +893.0% | — |
| Margins | ||||||||
| EBITDA margin | — | <−999% | <−999% | — | — | −571.5% | −478.8% | −505.2% |
| Operating margin | — | <−999% | <−999% | — | — | −584.2% | −488.2% | −516.9% |
| Net margin | — | −870.3% | <−999% | — | — | −705.3% | −411.8% | −432.7% |
| Free-cash-flow margin | — | −844.9% | <−999% | — | — | 20.1% | −381.3% | −530.3% |
| Cash flow | ||||||||
| Cash from operations | −8 | −9 | −8 | −6 | −5 | 0 | −6 | −9 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −9 | −9 | −8 | −6 | −5 | 0 | −7 | −9 |
| Stock-based pay | 4 | 4 | 4 | 3 | 2 | 2 | 2 | 2 |
| Free cash flow after stock pay | −13 | −13 | −12 | −9 | −7 | −2 | −9 | −11 |
| Last 12 months unless stated | RANI | ANL | BOLT | IVA | TRDA | OCGN | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $5m | $5m | $5m | $5m | $5m | $5m | $56m |
| Revenue growth, last 12 months | 306.4% | — | 12.8% | −49.1% | −94.1% | −3.7% | 12.6% |
| Revenue growth, 3-year average | — | — | −11.5% | — | — | 26.3% | 13.7% |
| Revenue growth, latest quarter | 893.0% | — | −99.7% | — | −53.9% | 8.4% | 10.2% |
| Operating margin | −675.8% | −714.0% | −654.5% | <−999% | <−999% | <−999% | −189.4% |
| Operating margin, 3-year average | <−999% | — | −887.4% | — | <−999% | <−999% | −363.5% |
| Net margin | −618.0% | −710.6% | −611.5% | <−999% | <−999% | <−999% | −169.8% |
| Cash from operations / revenue | −416.1% | −669.0% | −669.2% | <−999% | <−999% | <−999% | −168.0% |
| Free-cash-flow margin | −417.0% | −672.8% | −669.2% | — | <−999% | <−999% | −162.4% |
| Free-cash-flow margin, 3-year average | <−999% | — | −825.2% | — | <−999% | <−999% | −310.0% |
| Stock pay / revenue | 186.4% | 30.6% | 54.1% | 597.1% | 413.3% | 201.1% | 20.0% |
| Change in share count | — | 0.2% | 1.0% | 212.5% | −0.6% | 14.1% | 8.2% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 306.4% | 12.6% | 20 of 172 |
| Change in growth rate Growth | +142.3pp | -0.1pp | 15 of 172 |
| Operating margin Profitability | -675.8% | -189.4% | 128 of 175 |
| Net margin Profitability | -618.0% | -157.3% | 133 of 180 |
| Free-cash-flow margin Cash generation | -417.0% | -145.4% | 125 of 176 |
| Stock pay as % of revenue Cash generation | 186.4% | 19.2% | 152 of 179 |
| Long-term debt as % of assets Balance sheet | 0.0% | 20.6% | 1 of 78 |
| Days sales outstanding Balance sheet | 153 days | 75 days | 87 of 100 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Samsara Biocapital, LLC | $7.9M | 10.4M | 22.8% | ▲ 22.0% |
| RA Capital Management, L.P. | $6.5M | 8.5M | 18.7% | 0.0% |
| Awm Investment Company, Inc. | $5.7M | 7.5M | 16.5% | ▲ 15.4% |
| Vanguard Capital Management LLC | $3.5M | 4.6M | 10.0% | ▼ 1.3% |
| Longaeva Partners L.P. | $1.8M | 2.3M | 5.1% | 0.0% |
| Polar Asset Management Partners Inc. | $1.8M | 2.3M | 5.1% | New |
| Siren, L.L.C. | $1.5M | 2.0M | 4.4% | 0.0% |
| Heights Capital Management, Inc | $710,655 | 935K | 2.1% | New |
| Geode Capital Management, LLC | $677,575 | 891K | 2.0% | ▼ 1.4% |
| Citadel Advisors LLC | $488,173 | 642K | 1.4% | New |
| Marshall Wace, LLP | $445,561 | 586K | 1.3% | New |
| Nan Fung Group Holdings Ltd | $375,321 | 494K | 1.1% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Rani Therapeutics Holdings, Inc.'s complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Imran Mir A Director | July 21, 2026 | Buy | 36,000 | $0.69 | $24,840 |
| Imran Talat Chief Executive Officer | July 17, 2026 | Buy | 35,000 | $0.72 | $25,200 |
| Javadi Alireza Chief Technical Officer | March 27, 2026 | Sell | 386 | $0.78 | $301 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
